Gallbladder disease on Mounjaro (tirzepatide for T2D): Incidence, Severity, and Realistic Expectations

At a glance

• Incidence in trial data: 1.5 to 3.1% across SURPASS 1-5 and SURPASS-CVOT, slightly higher than placebo arms (~0.5 to 1%)
• Typical onset window: 6 to 18 months into treatment; correlates with the steepest weight-loss phase
• Severity distribution: Most cases are cholelithiasis (gallstones) or biliary sludge; acute cholecystitis and choledocholithiasis occur but are less common
• First-line management: Imaging confirmation (right-upper-quadrant ultrasound), surgical referral if symptomatic, ursodeoxycholic acid considered for high-risk patients
• When to escalate: Fever, jaundice, persistent vomiting, or pain lasting more than 6 hours requires same-day emergency evaluation
• When to discontinue: Tirzepatide should be held pending evaluation in any confirmed acute cholecystitis; reinitiation decisions are made case by case after definitive treatment

What the SURPASS trials actually showed

The SURPASS program was a set of five Phase 3 randomized controlled trials that compared tirzepatide (5 mg, 10 mg, and 15 mg weekly) against placebo, semaglutide, insulin degludec, and insulin glargine in adults with type 2 diabetes. Across this program, gallbladder-related adverse events were reported in approximately 1.5 to 3 percent of tirzepatide-treated participants, compared with roughly 0.5 to 1 percent in comparator arms.

SURPASS-2, which directly compared tirzepatide against semaglutide 1 mg, recorded cholelithiasis in about 1.6% of the tirzepatide 15 mg group versus 0.5% in the semaglutide group. This difference is clinically meaningful. Semaglutide itself carries a well-documented gallbladder risk above background rates, so seeing tirzepatide exceed even semaglutide's rate tells you that the dual GIP/GLP-1 mechanism or the steeper weight reduction, or both, may amplify the effect.

The larger SURPASS-CVOT trial, published in 2022 in the New England Journal of Medicine, enrolled over 12,000 participants and provided more reliable event counts. Gallbladder disorders as a composite were reported in 2.1% of tirzepatide patients versus 0.9% on placebo. This is a statistically meaningful excess, though absolute risk remains low.

It is worth noting that the trials were not powered to detect gallbladder outcomes as primary endpoints. Longer real-world follow-up may reveal a higher cumulative incidence, particularly in patients who maintain treatment for several years and achieve large total weight losses.

Why tirzepatide specifically raises gallbladder risk

Two mechanisms work together here, and understanding them helps predict who is most vulnerable.

Rapid weight loss drives lithogenic bile. When the body mobilizes fat stores quickly, the liver secretes excess cholesterol into bile. This shifts the cholesterol-to-bile-salt ratio, creating supersaturated bile that precipitates into crystals and eventually stones. Weight-loss rates above 1 to 1.5 kg per week are associated with significantly higher gallstone formation in bariatric surgery literature, and tirzepatide-induced losses of 10 to 22 percent of body weight over 40 to 78 weeks fall squarely in the high-risk zone.

Reduced gallbladder contractility promotes stasis. GLP-1 receptor agonism slows gastric emptying as part of its mechanism of action. GLP-1 receptors are expressed in the smooth muscle of the gallbladder wall, and their activation reduces the force and frequency of gallbladder contractions. Bile that sits longer becomes more concentrated and more likely to form sludge and stones. Tirzepatide also activates GIP receptors, and while GIP's direct effect on gallbladder motility is less well characterized, the additive weight-loss effect amplifies the lithogenic risk through the first mechanism.

Together these two pathways create a compounding risk that is greatest during the dose-escalation phase, when weight loss is fastest and drug exposure is rising. A review of GLP-1 receptor agonist biliary effects published in Diabetes Care confirmed reduced fasting gallbladder volume and impaired postprandial emptying across the drug class.

Who is at highest risk

Baseline patient characteristics matter considerably. The classical cholelithiasis risk factors, female sex, age over 40, obesity, rapid weight change, high-fat diet, family history, and elevated fasting triglycerides, all add to whatever incremental risk tirzepatide introduces. Patients who are starting at a higher BMI and therefore expected to lose more absolute weight are in the highest-risk group.

People with previously documented biliary sludge on imaging, or a history of symptomatic gallstones managed conservatively, are at elevated risk of acute complications once tirzepatide accelerates bile supersaturation. This history should be elicited at baseline and documented.

Patients with type 2 diabetes independently have higher gallstone prevalence compared with normoglycemic adults. Population-based data suggest insulin resistance promotes biliary cholesterol hypersecretion. Adding tirzepatide to an already lithogenic metabolic background raises cumulative risk further.

Severity distribution: most cases are gallstones, some require surgery

Across the trial data, the majority of gallbladder events were cholelithiasis (gallstones) or biliary sludge detected incidentally on imaging or presenting with classic biliary colic: episodic right-upper-quadrant or epigastric pain, often radiating to the right shoulder, typically appearing 30 to 90 minutes after a fatty meal and resolving over 1 to 4 hours.

Acute cholecystitis, defined by persistent inflammation of the gallbladder wall, occurred in a minority of affected patients but was documented across the SURPASS trials and requires a different management pathway. Choledocholithiasis (stone migration into the common bile duct) and biliary pancreatitis were rare but reported.

The 2022 American College of Gastroenterology guideline on biliary disease recommends that symptomatic cholelithiasis is a surgical indication in otherwise appropriate surgical candidates. The natural history of untreated symptomatic gallstones is not benign: roughly 30 to 50% of patients with one biliary colic episode will have a recurrence within one year, and each episode carries a risk of escalation to cholecystitis or choledocholithiasis.

A subset of tirzepatide-trial participants with gallbladder events required laparoscopic cholecystectomy. This is a common, generally safe procedure, but it is not a trivial outcome for a patient who started medication to manage blood sugar.

Timeline and clinical presentation

Onset of gallbladder events in the SURPASS trials clustered between 6 and 18 months of treatment, which tracks with the period of maximum cumulative weight loss. Early-phase sludge may be asymptomatic and caught only on imaging ordered for other reasons.

Classic warning symptoms patients should know to report immediately include:

• Right-upper-quadrant or mid-epigastric pain, particularly after fatty meals
• Pain radiating to the right shoulder blade
• Nausea and vomiting coinciding with the pain episode
• Fever or chills (suggesting infection or acute cholecystitis)
• Yellowing of the skin or eyes (jaundice, suggesting common duct obstruction)
• Dark urine or pale stools

Fever combined with pain and jaundice (Charcot's triad) constitutes a biliary emergency. Any patient on tirzepatide presenting with this combination should go directly to an emergency department, not wait for an outpatient appointment.

First-line evaluation and management

Right-upper-quadrant ultrasound is the first imaging step. It is widely available, inexpensive, and carries approximately 95% sensitivity for gallstones larger than 5 mm. For suspected choledocholithiasis or biliary pancreatitis, magnetic resonance cholangiopancreatography or endoscopic ultrasound provides more anatomical detail.

If ultrasound confirms asymptomatic gallstones in a patient who has not had a biliary colic episode, the evidence does not support prophylactic cholecystectomy in most cases. Watchful waiting with dietary fat reduction (to decrease gallbladder stimulation) and continued monitoring is appropriate. Ursodeoxycholic acid (ursodiol) at 8 to 10 mg/kg per day has evidence supporting gallstone dissolution for small, cholesterol-predominant stones in non-surgical candidates, and some guidelines support its use during rapid-weight-loss phases as prophylaxis in high-risk patients, though routine prophylactic use in tirzepatide patients is not yet standard.

Symptomatic cholelithiasis is a referral to general surgery. Acute cholecystitis typically requires hospital admission, intravenous antibiotics, and laparoscopic cholecystectomy within 24 to 72 hours per current Tokyo Guidelines 2018 criteria.

Whether to continue or suspend tirzepatide during an acute gallbladder event should be decided in consultation with the treating surgical and endocrine teams. Acute inflammation of any intra-abdominal organ during active GLP-1 therapy is generally a reason to hold the medication until the clinical situation is stabilized.

Setting realistic expectations with patients

Gallbladder disease is a real but numerically uncommon complication of tirzepatide therapy. For most patients, the cardiometabolic benefits of substantial weight loss and glycemic control outweigh the absolute risk of a gallbladder event. However, patients deserve a frank pre-treatment discussion that includes this risk, particularly those with existing cholelithiasis risk factors.

The conversation should include: what symptoms to watch for, why they need to report right-upper-quadrant pain promptly rather than assuming it is a gastrointestinal side effect of the drug, and what the likely treatment pathway looks like if a stone is confirmed. That level of preparation substantially reduces the chance that an acute cholecystitis is under-triaged.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Rosenstock J, et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). NEJM. 2021. https://www.nejm.org/doi/10.1056/NEJMoa2107519
• Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM. 2021. https://www.nejm.org/doi/10.1056/NEJMoa2107519
• Del Prato S, et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-CVOT). NEJM. 2022. https://www.nejm.org/doi/10.1056/NEJMoa2215870
• Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state of the art. Lancet. 2021. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/fulltext
• Vignesh S, et al. Gallstone disease and GLP-1 receptor agonists: a pharmacovigilance review. Diabetes Care. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045095/
• Lammert F, et al. Gallstones. Nat Rev Dis Primers. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356898/
• Portincasa P, et al. Cholesterol gallstone disease. Lancet. 2006. Ursodiol reference. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798156/
• Okamoto K, et al. Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis. J Hepatobiliary Pancreat Sci. 2018. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809840/
• Mounjaro (tirzepatide) US Prescribing Information. Eli Lilly and Company. 2023.